OpenBiome suspended distribution of investigational FMT on December 31, 2024, per final FDA decision.
Fecal microbiota transplantation (FMT) is considered an investigational new drug (IND), which typically requires an application to be filed; however, the FDA has released specific guidance related to these types of therapies.
There's more to see -- the rest of this topic is available only to subscribers.